# US 2026/0085087 A1 · Chemical compound comprising a triazine group and method for producing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085087 A1
- Document ID: US20260085087A1
- Status: Published application
- Kind: A1
- Application number: 18/031,420
- Filed: 2021-10-13
- Published: 2026-03-26
- Earliest claimed: 2020-10-12
- Inventors: Maxim Sergeevich KUPRYUSHKIN; Timofei Dmitrievich ZHARKOV; Ilya Sergeevich DOVYDENKO; Oleg Vladimirovich MARKOV
- Web page: https://patentgrep.com/patent/US20260085087A1

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 35/00: Antineoplastic agents
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.

## Claims

### Claim 1

A compound of Formula F0:
wherein Z is selected from the group of: —OH, —SH, —SeH, —NHRN, —O-PG, —S-PG, —Se-PG, or —N(PG)RN.
In an embodiment, X is selected from the group consisting of the 5′-O end of a nucleoside or oligonucleotide, and Y is selected from the group consisting of the 3′-O end of a nucleoside or oligonucleotide, —H, —OH, —SH, —NHRN, —O-PG, or —S-PG, a linker, a monophosphate, or a diphosphate.
In another embodiment, Y is selected from the group consisting of the 5′-O end of a nucleoside or oligonucleotide, and X is selected from the group consisting of the 3′-O end of a nucleoside or oligonucleotide, —H, —OH, —SH, —NHRN, —O-PG, or —S-PG, a linker, a monophosphate, or a diphosphate.
Substituents R1, R2, R3, R4 are selected from the series of —H, —C1-18alkyl, —C2-18alkenyl, —C2-18alkynyl, and —C6-18aryl, which may include the groups of —NH—, —N<, —O—, —NHC(O)—, —NHS(O)2—, —N(CH2CH2)2N−, and/or
and terminate in the groups of —NR2, —OR, —SR, —OC(O)R, —NHC(O)R, —C(O)OR, —C(O)NHR, —N═C(N(R2)2, —S(O)R, —S(O)2R, —S(O)2NR2, —CN, —Cl, —Br, —I, —F, —N3,
Substituents of R5, R6, R7, R8 are selected from the series comprising —H, —C1-18alkyl, —C2-18alkenyl, —C2-18alkynyl, and —C6-18aryl, which may include the groups of —NH—, —N<, —O—, —NHC(O)—, —NHS(O)2—, —N(CH2CH2)2N−, and terminate in the groups of —NR2, —OR, —SR, —OC(O)R, —NHC(O)R, —C(O)OR, —C(O)NHR, —N═C(N(R2))2, —S(O)R, —S(O)2R, —S(O)2NR2, —CN, —Cl, —Br, —I, —F, —N3.
Wherein R is a substituent selected from the series of —H, —C1-18alkyl, —C2-18alkenyl, —C2-18alkynyl, and —C6-18aryl, which may include the groups of —NH—, —N<, —O—, —NHC(O)—, —NHS(O)2—, —N(CH2CH2)2N−, and may terminate in the groups of —NRN2, —ORN, —SRN, —OC(O)RN, —NHC(O)RN, —C(O)ORN, —C(O)NHRN, —N═C(N(R2))2, —S(O)R, —S(O)2R, —S(O)2NR2, —CN, —Cl, —Br, —I, —F, —N3.
Wherein PG is a protecting group,
RN is —H or —C1-4alkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein substituents R1, R2, R3, R4 are selected from the series of —H, —C1-18alkyl, —C2-18alkenyl, —C2-18 alkynyl and —C6-18 aryl, which may include the groups of —NH—, —N<, —O—, —NHC(O)—, —NHS(O)2—, —N(CH2CH2)2N−, and/or

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1, R2, R3, R4 are selected from the series of —H, —C1-18alkyl, —C2-18alkenyl, —C2-18 alkynyl, and —C6-18 aryl, which may include the groups of —NR2, —OR, —SR, —OC(O)R, —NHC(O)R, —C(O)OR, —C(O)NHR, —N═C(N(R2)2, —S(O)R, —S(O)2R, —S(O)2NR2, —CN, —Cl, —Br, —I, —F, —N3,

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1═R3, R2═R4.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein R1═R3=—H or —CH3, R2═R4.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein R1═R3=—H or —CH3, R2═R4=—C1-18alkyl. or —C1-18 alkenyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R1 and R2 and/or R3 and R4 together form the ═C(NR2)2 group.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R1 and R2; R3 and R4; R5 and R6; R7 and R8 together with the atom to which they are bound form a 5-8-membered heterocyclic substituent selected from the group consisting of N-pyrrolidinyl, N-piperidinyl, N-azepanyl, N-azocanyl, or N-piperazinyl.

### Claim 9 (depends on 1)

A method for production of a compound according to claim 1 (F0), the method comprising interaction of a trivalent phosphorus derivative of Formula (F1) with an azidotriazine of Formula (F2) to give a compound of Formula (F3), with subsequent processing with amines HNR1R2, HNR3R4, or HNRXRY. Wherein substituents RX and RY will be converted to substituents R1, R2, R3, R4 using conversion reactions known in the art for the respective reactive groups included in RX and RY.
Substituents X, Y, Z are defined as in Formula (F0).
A and B may be independently selected from the series of —NR1R2, —NR3R4, —NRXRY, —Q.
Wherein Q is a group capable of taking part in replacement reactions. Q is selected from the series of: —OR, —OC(O)R, —OS(O)2R, —CN, —Cl, —Br, —I, —F, —N3. The Q group may be substituted by —NR1R2, —NR3R4, —NRXRY in a reaction with the respective amine HNR1R2, HNR3R4, HNRXRY.
Wherein substituents RX, RY are selected from the series comprising —H, —C1-18alkyl, —C2-18alkenyl, —C2-18 alkynyl and —C6-18aryl, which may include the groups of —NH—, —N<, —O—, —NHC(O)—, —NHS(O)2—, and/or —N(CH2CH2)2N−, and terminate in the groups of —NR2, —OR, —SR, —OC(O)R, —NHC(O)R, —C(O)OR, —C(O)NHR, —N═C(N(R2))2, —S(O)R, —S(O)2R, —S(O)2NR2, —CN, —Cl, —Br, —I, —F, —N3.
Wherein substituents R1, R2, R3, R4, R are as described in claim 1 (F0).

### Claim 10 (depends on 9)

The method for production of the compound according to claim 9, wherein a trivalent phosphorus derivate is an H-phosphonate unit produced according to the H-phosphonate oligonucleotide synthesis method, or a phosphite unit produced according to the phosphoramidite oligonucleotide synthesis method.

### Claim 11 (depends on 10)

The method according to claim 10, wherein A=B=—Q

### Claim 12 (depends on 11)

The method according to claim 11, wherein Q=Cl.

### Claim 13 (depends on 10)

The method according to claim 10, wherein A=—NR1R2, B=-Q.

### Claim 14 (depends on 13)

The method according to claim 13, wherein Q=Cl.

### Claim 15 (depends on 10)

The method according to claim 10, wherein A=—NR1R2, B=—NR3R4.

### Claim 16 (depends on 1)

An oligonucleotide wherein at least one modified phosphate group is as defined in Formula Fx:
wherein — — — — indicates an attachment of substituents respective for the oligonucleotide, and R1, R2, R3, and R4 are as defined in Formula (F0) according to claim 1.

### Claim 17 (depends on 16)

Use of oligonucleotide according to claim 16 as an exploratory means in vitro.

### Claim 18 (depends on 16)

Use of oligonucleotide according to claim 16 as an exploratory means in vivo.

### Claim 19 (depends on 16)

Use of oligonucleotide according to claim 16 as a diagnostic means.

### Claim 20 (depends on 16)

Use of oligonucleotide according to claim 16 as a therapeutic oligonucleotide.

### Claim 21 (depends on 16)

Use of oligonucleotide according to claim 16 as an antiviral agent.

### Claim 22 (depends on 16)

Use of oligonucleotide according to claim 16 as an antimicrobial agent.

### Claim 23 (depends on 16)

Use of oligonucleotide according to claim 16 as an anti-cancer agent.

### Claim 24 (depends on 16)

Use of oligonucleotide according to claim 16 as an anti-cancer agent modulating the micro-RNA expression.
